Innovative Immunotherapy Solutions for Cancer Treatment
At Immune Propulsion, our mission is to revolutionize cancer therapy through the innovative use of IdeS-cleaved antibodies. We aim to harness the body's immune system to restore and enhance the efficacy of both established anti-cancer monoclonal antibodies and natural host antitumor antibodies. Our groundbreaking approach is designed to address the complexities of solid tumors, improving patient outcomes and providing new avenues for treatment. We are driven by a commitment to scientific excellence, collaboration, and the relentless pursuit of knowledge in the field of immunotherapy.
Our dedicated team comprises leading researchers and medical professionals who specialize in cancer treatment and immunotherapy. With extensive experience in antibody engineering and tumor immunology, we are equipped to provide cutting-edge solutions that bridge the gap between laboratory research and clinical application. Our team is committed to fostering partnerships with institutions and researchers to further develop our innovative technologies. Together, we can pave the way for breakthrough therapies that redefine the landscape of cancer treatment.
Our Team
Dr. Robert Jordan, PhD.
Founder
40+ yr. industry veteran Bayer, Centocor, Janssen R&D (retired), Visiting Scholar – UT (Houston)
Mark Nedelman, MS, MBA
Partner
40+ yr. industry veteran MGH, Centocor, CRL, Biomere
Susan Tam, MS
Partner
35+ yr. industry veteran Centocor, Jansen R&D, Tavotek (co-founder)